Colorectal cancer. Malignant neoplasm of colon, unspecified
Conditions
Interventions
Intervention 1: Intervention 1: a 50000 IU vitamin D tablet (Zahravi, Iran), weekly+ 2 omega-3 fatty acid capsules (each capsule containing 330 mg omega-3 fatty acid) (Minami Nutrition, Belgium), dail
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with stage ?? or ??? colorectal cancer and were candidate to receive chemotherapy; aged 18 years or more; body mass index range of 18.5-30 kg/m2; serum 25(OH)D < 30 ng/ml; not having autoimmune or chronic diseases; not taking vitamin D and/or omeaga-3 supplements and other vitamin- mineral supplements or parenteral nutrition; not taking laxative and anti-inflammatory medications; not allergic to fish and fish products;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum TNF-a levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany). | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of Matrix Metalloproteinase-2 (MMP-2). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of MMP-2 will be assessed by ELISA and Zellbio kit (Zellbio, Germany).;Serum levels of Matrix Metalloproteinase-9 (MMP-9). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of MMP-9 will be assessed by ELISA and Zellbio kit (Zellbio, Germany).;Serum levels of Alkaline phosphatase (ALP). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of ALP will be assessed by ELISA and Zellbio kit (Zellbio, Germany). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammadreza Vafa
Iran University of Medical Sciences
Outcome results
None listed